Timothy Rolph - Mar 10, 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Scientific Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Mar 10, 2023
Transactions value $
-$26,212
Form type
4
Date filed
3/14/2023, 04:19 PM
Previous filing
Dec 30, 2022
Next filing
Jun 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Tax liability -$26.2K -603 -0.32% $43.47 190K Mar 10, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units.